HUE055942T2 - LPA génexpressziójának gátlására szolgáló készítmények és eljárások - Google Patents

LPA génexpressziójának gátlására szolgáló készítmények és eljárások

Info

Publication number: HUE055942T2
Authority: HU; Hungary
Prior art keywords: compositions; methods; gene expression; lpa gene; inhibiting lpa
Prior art date: 2015-10-01

Application number

HUE16852695A

Other languages

English (en)

Inventor

Stacey Melquist

Steven Kanner

David Rozema

David Lewis

Lauren Almeida

Darren Wakefield

Vladimir Trubetskoy

Tao Pei

Zhen Li

Aaron Almeida

Original Assignee

Arrowhead Pharmaceuticals Inc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2015-10-01

Filing date

2016-09-30

Publication date

2022-01-28

2016-09-30 Application filed by Arrowhead Pharmaceuticals Inc filed Critical Arrowhead Pharmaceuticals Inc

2022-01-28 Publication of HUE055942T2 publication Critical patent/HUE055942T2/hu

Classifications

- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
- C12N15/1137—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against enzymes
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
- C12Y304/21—Serine endopeptidases (3.4.21)
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/14—Type of nucleic acid interfering N.A.
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/31—Chemical structure of the backbone
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/31—Chemical structure of the backbone
- C12N2310/315—Phosphorothioates
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/32—Chemical structure of the sugar
- C12N2310/321—2'-O-R Modification
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/35—Nature of the modification
- C12N2310/351—Conjugate
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/35—Nature of the modification
- C12N2310/351—Conjugate
- C12N2310/3517—Marker; Tag

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Engineering & Computer Science (AREA)
Genetics & Genomics (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Biomedical Technology (AREA)
Bioinformatics & Cheminformatics (AREA)
Wood Science & Technology (AREA)
General Engineering & Computer Science (AREA)
Zoology (AREA)
Molecular Biology (AREA)
Biotechnology (AREA)
General Health & Medical Sciences (AREA)
Biochemistry (AREA)
Physics & Mathematics (AREA)
Microbiology (AREA)
Plant Pathology (AREA)
Biophysics (AREA)
Virology (AREA)
Veterinary Medicine (AREA)
Pharmacology & Pharmacy (AREA)
Medicinal Chemistry (AREA)
Animal Behavior & Ethology (AREA)
Public Health (AREA)
Epidemiology (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Cardiology (AREA)
Heart & Thoracic Surgery (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Medicinal Preparation (AREA)
Micro-Organisms Or Cultivation Processes Thereof (AREA)

HUE16852695A 2015-10-01 2016-09-30 LPA génexpressziójának gátlására szolgáló készítmények és eljárások HUE055942T2 (hu)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date
US201562235816P	2015-10-01	2015-10-01
US201662346304P	2016-06-06	2016-06-06
US201662383221P	2016-09-02	2016-09-02

Publications (1)

Publication Number	Publication Date
HUE055942T2 true HUE055942T2 (hu)	2022-01-28

Family

ID=58424351

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
HUE16852695A HUE055942T2 (hu)	2015-10-01	2016-09-30	LPA génexpressziójának gátlására szolgáló készítmények és eljárások

Country Status (38)

Country	Link
US (3)	US9932586B2 (hu)
EP (2)	EP3356529B1 (hu)
JP (4)	JP6991966B2 (hu)
KR (2)	KR20240162596A (hu)
CN (1)	CN108368506A (hu)
AU (2)	AU2016331084B2 (hu)
BR (1)	BR112018006489A2 (hu)
CA (1)	CA3000397A1 (hu)
CL (1)	CL2018000803A1 (hu)
CO (1)	CO2018003678A2 (hu)
CR (1)	CR20180231A (hu)
CY (1)	CY1125263T1 (hu)
DK (1)	DK3356529T3 (hu)
EA (1)	EA038478B1 (hu)
ES (1)	ES2896298T3 (hu)
HK (1)	HK1259063A1 (hu)
HR (1)	HRP20211410T1 (hu)
HU (1)	HUE055942T2 (hu)
IL (3)	IL300438A (hu)
JO (2)	JOP20210043A1 (hu)
LT (1)	LT3356529T (hu)
MA (1)	MA43347B1 (hu)
MX (2)	MX2018003833A (hu)
MY (1)	MY195796A (hu)
PE (1)	PE20181139A1 (hu)
PH (1)	PH12018500713A1 (hu)
PL (1)	PL3356529T3 (hu)
PT (1)	PT3356529T (hu)
RS (1)	RS62523B1 (hu)
SG (1)	SG10202008530TA (hu)
SI (1)	SI3356529T1 (hu)
SM (1)	SMT202100622T1 (hu)
TN (1)	TN2018000094A1 (hu)
TW (3)	TW202449154A (hu)
UA (1)	UA121998C2 (hu)
UY (1)	UY36926A (hu)
WO (1)	WO2017059223A2 (hu)
ZA (1)	ZA202106265B (hu)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US7718133B2 (en)	2003-10-09	2010-05-18	3M Innovative Properties Company	Multilayer processing devices and methods
CN109069529B (zh) *	2016-03-07	2021-08-20	箭头药业股份有限公司	用于治疗性化合物的靶向配体
TWI775743B (zh) *	2016-09-02	2022-09-01	美商愛羅海德製藥公司	標靶性配體
JP7155239B2 (ja)	2017-04-05	2022-10-18	サイレンス・セラピューティクス・ゲーエムベーハー	産物及び組成物
BR112019023650A2 (pt) *	2017-07-06	2020-06-02	Arrowhead Pharmaceuticals, Inc.	Agentes rnai para inibir a expressão de alfa-enac e métodos de uso
EP3681516A4 (en) *	2017-09-11	2021-09-29	Arrowhead Pharmaceuticals, Inc.	RNA INTERFERENCE AGENTS AND COMPOSITIONS INTENDED TO INHIBIT APOLIPOPROTEIN C-III (APOC3) EXPRESSION
JOP20200050A1 (ar) *	2017-09-14	2020-03-05	Arrowhead Pharmaceuticals Inc	عوامل RNAi وتركيبات لتثبيط التعبير عن شبيه آنجيوبويتين 3 (ANGPTL3)، وطرق استخدام
EP3697909A4 (en) *	2017-10-17	2021-10-13	Arrowhead Pharmaceuticals, Inc.	RNAI-BASED AGENTS AND COMPOSITIONS INTENDED TO INHIBIT ASIALOGLYCOPROTEIN RECEPTOR 1 EXPRESSION
EP3483270A1 (en) *	2017-11-13	2019-05-15	Silence Therapeutics GmbH	Products and compositions
EP3710586B1 (en) *	2017-11-13	2022-11-23	Silence Therapeutics GmbH	Nucleic acids for inhibiting expression of lpa in a cell
CA3109553A1 (en) *	2018-09-19	2020-03-26	Arrowhead Pharmaceuticals, Inc.	Rnai agents for inhibiting expression of 17beta-hsd type 13 (hsd17b13), compositions thereof, and methods of use
ES2932295T3 (es) *	2018-11-13	2023-01-17	Silence Therapeutics Gmbh	Acidos nucleicos para inhibir la expresión de LPA en una célula
WO2020247782A1 (en)	2019-06-06	2020-12-10	Avidity Biosciences, Inc.	Nucleic acid-polypeptide compositions and uses thereof
EP4073252A1 (en)	2019-12-09	2022-10-19	Amgen Inc.	Rnai constructs and methods for inhibiting lpa expression
BR112023001957A2 (pt)	2020-08-05	2023-04-25	Dicerna Pharmaceuticals Inc	Composições e métodos para inibir expressão de lpa
US20240035029A1 (en) *	2020-10-16	2024-02-01	Sanofi	Rna compositions and methods for inhibiting lipoprotein(a)
EP4240855A1 (en)	2020-11-05	2023-09-13	Amgen Inc.	Methods for treating atherosclerotic cardiovascular disease with lpa-targeted rnai constructs
WO2022121959A1 (zh) *	2020-12-09	2022-06-16	纳肽得有限公司	siRNA分子及其在治疗冠状动脉疾病中的应用
WO2022136466A1 (en)	2020-12-23	2022-06-30	Argonaute RNA Limited	Treatment of cardiovascular disease
CN117836307A (zh)	2021-06-18	2024-04-05	弘景生物科技有限公司	功能化的n-乙酰基半乳糖胺核苷
US11692001B2 (en)	2021-08-30	2023-07-04	Hongene Biotech Corporation	Functionalized n-acetylgalactosamine analogs
JP2024531728A (ja)	2021-09-14	2024-08-29	アルゴノートアールエヌエーリミテッド	心血管疾患の処置
KR20240056619A (ko) *	2021-09-18	2024-04-30	제노바 테라퓨틱스 컴퍼니 리미티드	Lpa 억제제 및 이의 용도
JP2024546585A (ja)	2021-12-15	2024-12-26	ホンジーンバイオテックコーポレイション	官能基化ｎ－アセチルガラクトサミンアナログ
CA3240604A1 (en) *	2021-12-16	2023-06-22	Yunfei Li	Lpa-targeting sirna and conjugate
CN114703184B (zh) *	2022-03-11	2024-06-18	厦门甘宝利生物医药有限公司	Lpa抑制剂及其用途
WO2024032681A1 (zh) *	2022-08-11	2024-02-15	益杰立科(上海)生物科技有限公司	一种表观编辑靶点的方法及用途
CN115851723B (zh) *	2022-10-24	2023-10-03	厦门甘宝利生物医药有限公司	一种抑制lpa基因表达的rna抑制剂及其应用
US12116382B2 (en)	2022-11-28	2024-10-15	Hongene Biotech Corporation	Functionalized N-acetylgalactosamine analogs
WO2024151937A1 (en) *	2023-01-13	2024-07-18	Eli Lilly And Company	Therapeutic oligonucleotide-containing pharmaceutical compositions and dosing regimens using the same
CN118773191A (zh) *	2023-04-03	2024-10-15	翰森（上海）健康科技有限公司	靶向LPA基因的RNAi剂及其用途
WO2024222686A1 (zh) *	2023-04-24	2024-10-31	上海京新生物医药有限公司	用于抑制LPA表达的RNAi剂及其应用
CN119343449A (zh) *	2023-05-24	2025-01-21	云合智药（苏州）生物科技有限公司	用于抑制angptl3表达的rnai剂及其应用
WO2024249680A2 (en) *	2023-05-31	2024-12-05	Arrowhead Pharmaceuticals, Inc.	Hepatic Delivery Platforms For Multimeric RNAi Agent Conjugates and Methods of Use Thereof
WO2024245410A1 (zh) *	2023-05-31	2024-12-05	上海拓界生物医药科技有限公司	一种靶向LPA的dsRNA及其应用

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
NL9201440A (nl)	1992-08-11	1994-03-01	Univ Leiden	Triantennaire clusterglycosiden, hun bereiding en toepassing.
US5599706A (en)	1994-09-23	1997-02-04	Stinchcomb; Dan T.	Ribozymes targeted to apo(a) mRNA
EP1159441B8 (en)	1999-03-10	2008-10-29	Marie Curie Cancer Care	Delivery of nucleic acids and proteins to cells
KR100872437B1 (ko) *	2000-12-01	2008-12-05	막스-플랑크-게젤샤프트 츄어 푀르더룽 데어 비쎈샤프텐 에.파우.	Ｒｎａ 간섭을 매개하는 작은 ｒｎａ 분자
US7259150B2 (en) *	2001-08-07	2007-08-21	Isis Pharmaceuticals, Inc.	Modulation of apolipoprotein (a) expression
US7227014B2 (en)	2001-08-07	2007-06-05	Isis Pharmaceuticals, Inc.	Antisense modulation of apolipoprotein (a) expression
EP1613348B1 (en)	2003-03-12	2010-06-23	The Arizona Board of Regents on Behalf of the University of Arizona	Methods for modulating angiogenesis with apelin compositions
US8084599B2 (en)	2004-03-15	2011-12-27	City Of Hope	Methods and compositions for the specific inhibition of gene expression by double-stranded RNA
CA2660842C (en)	2006-08-18	2012-03-13	F. Hoffmann-La Roche Ag	Polyconjugates for in vivo delivery of polynucleotides
US20100249214A1 (en)	2009-02-11	2010-09-30	Dicerna Pharmaceuticals	Multiplex dicer substrate rna interference molecules having joining sequences
EP2379083B1 (en)	2008-12-18	2017-08-16	Dicerna Pharmaceuticals, Inc.	Extended dicer substrate agents and methods for the specific inhibition of gene expression
CA2788600C (en)	2010-02-24	2019-12-03	Arrowhead Research Corporation	Compositions for targeted delivery of sirna
US8865675B2 (en) *	2010-05-12	2014-10-21	Protiva Biotherapeutics, Inc.	Compositions and methods for silencing apolipoprotein B
US8501930B2 (en) *	2010-12-17	2013-08-06	Arrowhead Madison Inc.	Peptide-based in vivo siRNA delivery system
RU2013117288A (ru) *	2010-12-17	2015-01-27	Эрроухэд Рисерч Корпорейшн	СОДЕРЖАЩАЯ ГАЛАКТОЗНЫЙ КЛАСТЕР НАЦЕЛИВАЮЩАЯ ГРУППА ДЛЯ миРНК, МОДУЛИРУЮЩАЯ ФОРМАКОКИНЕТИЧЕСКИЕ СВОЙСТВА
MX341118B (es)	2010-12-29	2016-08-09	Arrowhead Res Corp	Cojugados de suministro de polinucleotidos in vivo que tienen acoplamientos sensibles a enzima.
BR112014004585A2 (pt)	2011-08-26	2017-06-13	Arrowhead Res Corp	polímeros de poli(éster vinílico) para liberação de ácido nucleico in vivo
CA2856243A1 (en) *	2011-11-18	2013-05-23	Alnylam Pharmaceuticals, Inc.	Rnai agents, compositions and methods of use thereof for treating transthyretin (ttr) associated diseases
US8933047B2 (en)	2012-04-18	2015-01-13	Arrowhead Madison Inc.	Poly(acrylate) polymers for in vivo nucleic acid delivery
EP3822352A3 (en) *	2012-05-24	2021-11-03	Ionis Pharmaceuticals, Inc.	Methods and compositions for modulating apolipoprotein(a) expression
EP3566750A3 (en) *	2013-02-28	2020-04-08	ImmunoGen, Inc.	Conjugates comprising cell-binding agents and cytotoxic agents
BR112015027369B1 (pt)	2013-05-01	2021-06-08	Ionis Pharmaceuticals, Inc	compostos compreendendo um oligonucleotídeo modificado e um grupo de conjugado, composição compreendendo os referidos compostos e usos dos mesmos
WO2016149020A1 (en) *	2015-03-17	2016-09-22	Arrowhead Research Corporation	Rna interference agents
KR20180011198A (ko)	2015-05-29	2018-01-31	애로우헤드 파마슈티컬스 인코포레이티드	ＨＩＦ２α의 유전자 발현을 억제하는 조성물 및 방법
IL313082A (en) *	2015-07-31	2024-07-01	Alnylam Pharmaceuticals Inc	Transthyretin (TTR) iRNA compositions and methods of using them for the treatment or prevention of TTR-related diseases
CN109069529B (zh)	2016-03-07	2021-08-20	箭头药业股份有限公司	用于治疗性化合物的靶向配体

2015
- 2015-10-01 JO JOP/2021/0043A patent/JOP20210043A1/ar unknown
2016
- 2016-09-28 JO JOP/2016/0211A patent/JOP20160211B1/ar active
- 2016-09-30 CA CA3000397A patent/CA3000397A1/en active Pending
- 2016-09-30 TN TNP/2018/000094A patent/TN2018000094A1/en unknown
- 2016-09-30 HU HUE16852695A patent/HUE055942T2/hu unknown
- 2016-09-30 TW TW113106862A patent/TW202449154A/zh unknown
- 2016-09-30 KR KR1020247036942A patent/KR20240162596A/ko active Pending
- 2016-09-30 BR BR112018006489-0A patent/BR112018006489A2/pt active Search and Examination
- 2016-09-30 PE PE2018000487A patent/PE20181139A1/es unknown
- 2016-09-30 EP EP16852695.2A patent/EP3356529B1/en active Active
- 2016-09-30 PT PT168526952T patent/PT3356529T/pt unknown
- 2016-09-30 US US15/281,309 patent/US9932586B2/en active Active
- 2016-09-30 RS RS20211351A patent/RS62523B1/sr unknown
- 2016-09-30 WO PCT/US2016/054729 patent/WO2017059223A2/en active Application Filing
- 2016-09-30 CN CN201680057095.8A patent/CN108368506A/zh active Pending
- 2016-09-30 SG SG10202008530TA patent/SG10202008530TA/en unknown
- 2016-09-30 MY MYPI2018000440A patent/MY195796A/en unknown
- 2016-09-30 CR CR20180231A patent/CR20180231A/es unknown
- 2016-09-30 ES ES16852695T patent/ES2896298T3/es active Active
- 2016-09-30 UY UY0001036926A patent/UY36926A/es active IP Right Grant
- 2016-09-30 TW TW105131823A patent/TWI784934B/zh active
- 2016-09-30 PL PL16852695T patent/PL3356529T3/pl unknown
- 2016-09-30 LT LTEPPCT/US2016/054729T patent/LT3356529T/lt unknown
- 2016-09-30 MX MX2018003833A patent/MX2018003833A/es unknown
- 2016-09-30 AU AU2016331084A patent/AU2016331084B2/en active Active
- 2016-09-30 SI SI201631374T patent/SI3356529T1/sl unknown
- 2016-09-30 SM SM20210622T patent/SMT202100622T1/it unknown
- 2016-09-30 KR KR1020187010095A patent/KR102728481B1/ko active Active
- 2016-09-30 EP EP21191363.7A patent/EP4029941A1/en active Pending
- 2016-09-30 DK DK16852695.2T patent/DK3356529T3/da active
- 2016-09-30 EA EA201890864A patent/EA038478B1/ru unknown
- 2016-09-30 HR HRP20211410TT patent/HRP20211410T1/hr unknown
- 2016-09-30 UA UAA201804593A patent/UA121998C2/uk unknown
- 2016-09-30 TW TW111141660A patent/TWI836693B/zh active
- 2016-09-30 IL IL300438A patent/IL300438A/en unknown
- 2016-09-30 JP JP2018516738A patent/JP6991966B2/ja active Active
2017
- 2017-04-06 MA MA43347A patent/MA43347B1/fr unknown
2018
- 2018-02-21 US US15/901,810 patent/US10662427B2/en active Active
- 2018-03-25 IL IL258333A patent/IL258333B/en unknown
- 2018-03-27 MX MX2022013010A patent/MX2022013010A/es unknown
- 2018-03-28 PH PH12018500713A patent/PH12018500713A1/en unknown
- 2018-03-28 CL CL2018000803A patent/CL2018000803A1/es unknown
- 2018-04-05 CO CONC2018/0003678A patent/CO2018003678A2/es unknown
2019
- 2019-01-29 HK HK19101563.4A patent/HK1259063A1/zh unknown
2020
- 2020-05-06 US US16/867,925 patent/US20200263179A1/en not_active Abandoned
2021
- 2021-03-12 JP JP2021039949A patent/JP7116212B2/ja active Active
- 2021-08-30 ZA ZA2021/06265A patent/ZA202106265B/en unknown
- 2021-11-08 CY CY20211100962T patent/CY1125263T1/el unknown
2022
- 2022-02-13 IL IL290566A patent/IL290566B2/en unknown
- 2022-06-15 JP JP2022096415A patent/JP7442574B2/ja active Active
- 2022-12-05 AU AU2022283623A patent/AU2022283623A1/en active Pending
2023
- 2023-11-27 JP JP2023199857A patent/JP2024009262A/ja active Pending

Also Published As

Publication number	Publication date
JP2018529732A (ja)	2018-10-11
ZA202106265B (en)	2023-08-30
IL290566B1 (en)	2023-03-01
WO2017059223A2 (en)	2017-04-06
CL2018000803A1 (es)	2018-08-31
TW202332769A (zh)	2023-08-16
JP7442574B2 (ja)	2024-03-04
ES2896298T3 (es)	2022-02-24
JOP20210043A1 (ar)	2017-06-16
WO2017059223A9 (en)	2017-08-17
WO2017059223A3 (en)	2017-05-11
CR20180231A (es)	2018-05-31
PL3356529T3 (pl)	2021-12-20
IL290566A (en)	2022-04-01
KR20180052703A (ko)	2018-05-18
CN108368506A (zh)	2018-08-03
KR102728481B1 (ko)	2024-11-12
US20200263179A1 (en)	2020-08-20
KR20240162596A (ko)	2024-11-15
PH12018500713A1 (en)	2018-10-15
JP7116212B2 (ja)	2022-08-09
MY195796A (en)	2023-02-21
PT3356529T (pt)	2021-11-04
IL290566B2 (en)	2023-07-01
AU2016331084A1 (en)	2018-04-19
SMT202100622T1 (it)	2022-01-10
EP3356529B1 (en)	2021-08-25
TW201726918A (zh)	2017-08-01
IL300438A (en)	2023-04-01
CO2018003678A2 (es)	2018-11-30
EA201890864A1 (ru)	2018-09-28
US9932586B2 (en)	2018-04-03
TWI784934B (zh)	2022-12-01
RS62523B1 (sr)	2021-11-30
BR112018006489A2 (pt)	2018-10-09
SG10202008530TA (en)	2020-10-29
UY36926A (es)	2017-04-28
TW202449154A (zh)	2024-12-16
AU2016331084B2 (en)	2022-09-08
CY1125263T1 (el)	2023-03-24
EP4029941A1 (en)	2022-07-20
EP3356529A4 (en)	2019-09-04
IL258333A (en)	2018-05-31
JP2022113835A (ja)	2022-08-04
DK3356529T3 (da)	2021-11-08
EP3356529A2 (en)	2018-08-08
HRP20211410T1 (hr)	2021-12-24
US20170096665A1 (en)	2017-04-06
TWI836693B (zh)	2024-03-21
SI3356529T1 (sl)	2022-01-31
MA43347A (fr)	2018-08-08
JOP20160211B1 (ar)	2021-08-17
US10662427B2 (en)	2020-05-26
NZ741086A (en)	2023-11-24
LT3356529T (lt)	2021-12-27
JP2024009262A (ja)	2024-01-19
PE20181139A1 (es)	2018-07-17
CA3000397A1 (en)	2017-04-06
MX2022013010A (es)	2022-11-09
AU2022283623A1 (en)	2023-02-02
US20180195070A1 (en)	2018-07-12
TN2018000094A1 (en)	2019-07-08
JP6991966B2 (ja)	2022-02-03
MX2018003833A (es)	2018-06-18
EA038478B1 (ru)	2021-09-03
IL258333B (en)	2022-03-01
HK1259063A1 (zh)	2019-11-22
MA43347B1 (fr)	2021-11-30
UA121998C2 (uk)	2020-08-25
JP2021087459A (ja)	2021-06-10

Publication	Publication Date	Title
HUE055942T2 (hu)	2022-01-28	LPA génexpressziójának gátlására szolgáló készítmények és eljárások
HK1257295A1 (zh)	2019-10-18	用於免疫腫瘤學的組合物和方法
HUE063026T2 (hu)	2023-12-28	Eljárások és készítmények LDHA expressziójának gátlására
HK1258310A1 (zh)	2019-11-08	用於抑制譜系特異性抗原的組合物和方法
HK1250255A1 (zh)	2018-12-07	用於調節c9orf72表達的組合物
ME03003B (me)	2018-10-20	Kompozicije koje sadrže bakterijske sojeve
DK3274430T3 (da)	2022-10-03	Mikroalgesammensætninger og deres anvendelser
DK3234160T3 (da)	2019-12-02	Sammensætninger og fremgangsmåder til hjælper-stamme-medieret svampegenommodifikation
HUS2000034I1 (hu)	2020-09-28	Az ALAS1 gén expressziójának gátlására szolgáló készítmények és eljárások
EP3398996A4 (en)	2019-07-31	COMPOSITION
KR20180084891A (ko)	2018-07-25	구조 조성물 및 방법
DK3250182T3 (da)	2023-06-26	Dispergible sammensætninger
DK3334726T3 (da)	2022-05-16	Plinabulinsammensætninger
HUE054673T2 (hu)	2021-09-28	Rák kezelésére szolgáló eljárások és készítmények
HK1252852A1 (zh)	2019-06-06	阻止HIF2α基因表達的組合物及方法
DK3129007T3 (da)	2020-11-02	Vaccinesammensætninger
EP3560512A4 (en)	2020-07-22	COMPOSITION OF VACCINE AGAINST ZONA
EP3395887C0 (en)	2024-08-28	Fluororubber composition
DK3331498T3 (da)	2020-06-15	Nasalsammensætning
DK3393254T3 (da)	2021-07-26	Sammensætning
EP3369418A4 (en)	2019-07-31	COMPOSITION
DK3316857T3 (da)	2021-10-18	Multifasiske sammensætninger
EP3337518A4 (en)	2019-06-12	BAG3 COMPOSITIONS AND METHOD
DK3322295T3 (da)	2022-12-19	Sammensætning
DK3288536T3 (da)	2019-09-23	Sammensætninger omfattende anakinra